Peptides DB
Research-centric peptide and protocol reference hub

Lypressin record · updated 7h ago

Neuro & moodHealing & recoveryGrade A · human clinicalResearch use only
All 15 studiesJump to the evidenceCompare
What is Lypressin used for?

Research peptide discovered via AI researcher. peptide-based therapeutic

How it works: V1 and V2 receptor agonist

Primarily researched for · Neuro & moodRoute · Subcutaneous injection

Development stage

where Lypressin sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 122 registered trials. It describes the research record, not a recommendation.

Identity
NameLypressin
Chain length—
Molecular weight1,056.2 Da
FormulaC46H65N13O12S2
Structure typeNot established
ClassMetabolic
Research levelPreclinical
Discovered byThe Librarian · 2026

Mass and formula from PubChem CID 644076. No verified residue count for this compound.

Pharmacology
MechanismV1 and V2 receptor agonist
RouteSubcutaneous injection
Half-life—
Time to peak—
Duration—
Extraction confidence0.80
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Oct 20, 2026. How this works →
Research stats
Total studies15
Human / animal / cellular7 / 4 / 0
Highest trial phasePreclinical
Years covered1984–2026
Latest study16d ago
Publication history
19842026
Research funding
—no NIH grants found
Safety signals
FAERS reports907
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

15 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Diagnostic challenges of masked arginine vasopressin deficiency in neurosarcoidosis complicated by sodium-glucose cotransporter 2 inhibitor use.
FindingNot reported in abstract.
Human2023Full text read0.80
Development of a liquid chromatography coupled to tandem mass spectrometry method for the quantification of Arginine Vasopressin in human plasma.
Findingvalidated over a concentration range from 0.2 ng/L to 60 ng/L
Human2026Full text read0.80
Nursing intensity trajectory patterns and clinical outcomes in intensive care units: a latent class analysis.
FindingRapid Improvement associated with 74% lower mortality odds (OR = 0.26, 95% CI: 0.18-0.36, p < 0.001).
Human2026Full text read0.90
Beyond the pump: integrating the heart's endocrine function into early medical education.
TakeawayIntegrating the heart's endocrine function into medical education may enhance learners' understanding of structure-function relationships and clinical reasoning.
review2026Full text read0.80
Integrated Phytochemical Characterisation, Pharmacological Evaluation and Computational Investigation of Acampe papillosa Stem Extract.
FindingRectal temperature reduced to 98.04 ± 0.05°F at 21 h post-treatment.
Animal2026Full text read0.80
Research progress on the role and mechanism of STIM and Orai protein-mediated store-operated calcium entry in cardiovascular diseases.
TakeawaySOCE plays a complex role in cardiovascular diseases, and while inhibitors show promise in preclinical studies, clinical translation faces significant hurdles.
review2026Full text read0.90
Effects of lysine-vasopressin (LVP) and 1-deamino-8-D-arginine-vasopressin (dDAVP) upon electrical potential, short-circuit current and transepithelial D.C. resistance of the frog skin.
FindingStimulation by dDAVP was delayed by about 30 min compared to LVP (P < 0.01).
Animal1984Full text read0.80
Excitation of neurones in the rat paraventricular nucleus in vitro by vasopressin and oxytocin.
Finding66% of ninety-seven p.v.n. cells showed excitatory responses to AVP.
Animal1986Full text read0.80
Poor sleep quality and its association patterns with eating disorders, body composition and physical activity among university students in Douala-Cameroon.
Finding73.7% prevalence of poor sleep quality among students.
Human2026Full text read0.80
Randomized controlled trial of desmopressin plus terlipressin vs. terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: a multicenter, double-blind study. New Italian Endoscopic Club.
TakeawayNot reported in abstract.
—1993Title only0.10
MedFusion-gP-AKI: development and multicenter validation of a machine learning fusion model for early prediction of KDIGO stage 3 acute kidney injury in critically ill traumatic cervicothoracic spinal cord injury patients.
FindingAUC of 0.938 for model performance.
Human2026Full text read0.80
Prevalence and impact of hyponatremia in chronic obstructive pulmonary disease. A systematic review and meta-analysis.
FindingPooled prevalence of hyponatremia among COPD patients was 14% (95% CI: 4%-28%).
review2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Lypressin will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Lypressin is discussed should be drawn from it.